Halozyme Therapeutics Inc

1HALO

Company Profile

  • Business description

    Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

  • Contact

    12390 El Camino Real
    San DiegoCA92130
    USA

    T: +1 858 794-8889

    E: [email protected]

    https://www.halozyme.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    423

Stocks News & Analysis

stocks

The 5 best US dividend aristocrats to watch in 2026

How to avoid the dividend aristocrat trap.
stocks

Chart of the Week: Is CSL finally turning the ship around?

The beaten down healthcare giant remains cheap on turnaround potential.
stocks

ASX top pick remains cheap with narrowing brand focus

Shares remain cheap for ASX winemaker as the company narrows focus on high margin brands.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,836.7071.200.81%
CAC 408,206.7144.880.55%
DAX 4024,188.636.68-0.03%
Dow JONES (US)49,918.78953.33-1.87%
FTSE 10010,330.9176.100.74%
HKSE24,249.29158.67-0.65%
NASDAQ25,169.50509.32-1.98%
Nikkei 22564,217.2738.000.06%
NZX 50 Index13,202.1651.49-0.39%
S&P 5007,266.990.000.00%
S&P/ASX 2008,633.2069.700.81%
SSE Composite Index3,987.016.21-0.16%

Market Movers